Michael Schlander
Overview
Explore the profile of Michael Schlander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cheng C, Calderazzo S, Schramm C, Schlander M
MDM Policy Pract
. 2023 Jan;
8(1):23814683221145701.
PMID: 36698854
Highlights: This article presents a new discrete event simulation model, DECAS, which models both adenoma-carcinoma and serrated neoplasia pathways for colorectal cancer (CRC) development and CRC screening effects.DECAS is calibrated...
12.
Khan S, Hernandez-Villafuerte K, Hernandez D, Schlander M
Front Public Health
. 2023 Jan;
10:946544.
PMID: 36684975
Breast cancer (BC) is a heterogeneous disease representing a substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need to be fully...
13.
Schneider J, Hernandez D, Schlander M, Arndt V
J Cancer Surviv
. 2022 Dec;
17(6):1639-1659.
PMID: 36459378
Purpose: This study aims to examine the magnitude of out of pocket (OOP) payments and income loss, as well as to identify socioeconomic and clinical factors among long-term breast cancer...
14.
Muchadeyi M, Hernandez-Villafuerte K, Schlander M
BMC Med Res Methodol
. 2022 Nov;
22(1):303.
PMID: 36434521
Background: Health state utility values (HSUVs) are an essential input parameter to cost-utility analysis (CUA). Systematic literature reviews (SLRs) provide summarized information for selecting utility values from an increasing number...
15.
Hernandez D, Wagner F, Hernandez-Villafuerte K, Schlander M
J Gastrointest Cancer
. 2022 Apr;
54(2):391-407.
PMID: 35474568
Purpose: Pancreatic cancer is characterized by its high mortality, usually attributed to its diagnosis in already advanced stages. This article aims at presenting an overview of the economic burden of...
16.
Brougham M, Schlander M, Telser H, Bakshi S, Sola-Morales O
Expert Rev Pharmacoecon Outcomes Res
. 2022 Apr;
22(6):913-918.
PMID: 35400272
Introduction: Drug reimbursement decisions that spark public controversy are potential signals that processes used to reach such decisions do not adequately reflect society's goals. Such controversial decisions appear to be...
17.
Schlander M, Richardson J
Health Aff (Millwood)
. 2022 Apr;
41(4):609-610.
PMID: 35377751
No abstract available.
18.
Eckford R, Gaisser A, Arndt V, Baumann M, Kludt E, Mehlis K, et al.
Front Public Health
. 2022 Feb;
9:788598.
PMID: 35223757
In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, governments imposed various measures to decrease the rate of disease spread, and health care policy makers prioritized resource allocation to...
19.
Gaisser A, Eckford R, Arndt V, Doege D, Kludt E, Ubels J, et al.
Onkologe (Berl)
. 2022 Feb;
28(3):248-252.
PMID: 35106030
No abstract available.
20.
Moro D, Schlander M, Telser H, Sola-Morales O, Clark M, Olaye A, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2021 Dec;
22(4):581-598.
PMID: 34877915
Background: Conventional cost-effectiveness analysis [CEA] using cost per QALY thresholds may counteract other incentives introduced to foster development of treatments for rare and ultra-rare diseases. Therefore, alternative economic evaluation methods...